Pharma Journalist -

Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with…
Read More...

We are excited to release the agenda for the Innate Immune Stimulating Therapies Summit, running virtually on Wednesday, July 22 at 09.00 Eastern Time. Join the first…
Read More...

JAK inhibitors have been hotly pursued by the biopharmaceutical industry as new players in the field of immune-mediated diseases. This year, and with COVID-19 on the top of the agenda…
Read More...

Predictive Oncology Inc. announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of…
Read More...

Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced that it has entered into two strategic…
Read More...

AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation…
Read More...

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line…
Read More...

Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expansion of their existing collaboration to provide Regeneron with rights to develop products for…
Read More...

AbbVie and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 …
Read More...